P
Pieter J. Peeters
Researcher at Janssen Pharmaceutica
Publications - 49
Citations - 2898
Pieter J. Peeters is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Receptor & Fusion gene. The author has an hindex of 28, co-authored 45 publications receiving 2613 citations. Previous affiliations of Pieter J. Peeters include Johnson & Johnson Pharmaceutical Research and Development & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia
Pieter J. Peeters,Sophie Raynaud,Jan Cools,Iwona Wlodarska,J. Grosgeorge,Patrick Philip,Fabrice Monpoux,Luc Van Rompaey,Mathijs Baens,Herman Van den Berghe,Peter Marynen +10 more
TL;DR: JAK2 plays a central role in non-protein tyrosine kinase receptor signaling pathways, which could explain its involvement in malignancies of different hematologic lineages and in Drosophila no member of the JAK family has yet been implicated in tumorigenesis.
Journal ArticleDOI
Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
J Schwaller,J Frantsve,Jon C. Aster,Ifor R. Williams,Michael H. Tomasson,Theodora S. Ross,Pieter J. Peeters,L Van Rompaey,R A Van Etten,R. L. Ilaria,Peter Marynen,D. G. Gilliland,D. G. Gilliland +12 more
TL;DR: All human TEL/JAK2 fusion variants are oncoproteins in vitro that strongly activate STAT 5, and cause lethal myelo‐ and lymphoproliferative syndromes in murine bone marrow transplant models of leukemia.
Journal ArticleDOI
Variants in the FTO gene are associated with common obesity in the Belgian population
Armand V. Peeters,Sigri Beckers,An Verrijken,Peter Walter Maria Roevens,Pieter J. Peeters,Luc Van Gaal,Wim Van Hul +6 more
TL;DR: Both SNPs in the FTO gene were significantly associated with obesity, enabling us to replicate earlier findings from Caucasian cohorts in a Belgian population sample.
Journal ArticleDOI
A genetics-led approach defines the drug target landscape of 30 immune-related traits
Hai Fang,H De Wolf,B Knezevic,Katie L. Burnham,Julie A Osgood,A Sanniti,A Lledó Lara,Silva Kasela,S De Cesco,Jörg K. Wegner,Lahiru Handunnetthi,Fiona E. McCann,L Chen,Takuya Sekine,Paul Brennan,Paul Brennan,Brian D. Marsden,Brian D. Marsden,David R. Damerell,Christopher A. O’Callaghan,Christopher A. O’Callaghan,C. Bountra,Paul Bowness,Paul Bowness,Yvonne Sundström,Lili Milani,Louise Berg,Hinrich W. H. Göhlmann,Pieter J. Peeters,Benjamin P. Fairfax,Michael Sundström,Julian C. Knight,Julian C. Knight +32 more
TL;DR: It is demonstrated how the genetics-led drug target prioritization approach (the priority index) successfully identifies current therapeutics, predicts activity in high-throughput cellular screens, enables prioritization of under-explored targets and allows for determination of target-level trait relationships.
Journal Article
Fusion of ETV6 to MDS1/EVI1 as a Result of t(3;12)(q26;p13) in Myeloproliferative Disorders
Pieter J. Peeters,I. Wlodarska,Mathijs Baens,Arnold Criel,Dominik Selleslag,Anne Hagemeijer,H. Van den Berghe,Peter Marynen +7 more
TL;DR: A fusion between ETV6 on 12p13 and MDS1/EVI1 on 3q26 in a t(3;12)(q26;p13) found in two cases of myeloproliferative disorder is identified.